抗糖尿病新药物维格列汀的研究进展(2)
综上所述，维格列汀在临床研究中显示了良好的抗糖尿病作用，该药通过多种机制发挥其降血糖作用，克服了当前一些药物致低血糖的副作用，并且能改善胰岛功能，改变糖尿病患者病情不断恶化的状况，为糖尿病患者提供了更多的选择余地。
[参考文献]
[1]Mclntosh CH，Demuth HU，Kim SJ，et al. Applications of dipeptidyl peptidase Ⅳ inhibitors in diabetes mellitus [J]. Int J Biochem Cell Biol，2006，38(5-6)：860-872.
[2]Kiffer TJ，McIntosh CH，Pederson TA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl Peptidase Ⅳ[J]. Endocrin，1995，136(8)：3585-3596.
, http://www.100md.com
[3]Tran P，Yin H，Smith T，et al. Disposition of LAF237 in rats and humans [J]. Drug Metab Rev，2002，34(Suppl)：147.
[4]Villhanuer EB，Brinkman JA，Naderi GB，et al. I-[[(3-hydroxy-l-adamantyI)amino] acetyI]-2-cyano-(S)-pyrrolidine；a potent，selective，and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyper glycemic properties [J]. J Med Chem，2003，46(13)：2774-2789.
[5]He YL，Sabo R，Wang G，et al. The hepatic impairment on the pharmacokinetics of vildagliptin [M]. Washington，DC：66th Scientific Session of the American Diabetes Association，2006：1176-1179.
, 百拇医药
[6]Ristic S，Byiers S，Foley J，et al. Improved glycemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes：vildagliptin(LAF237)dose response [J]. Diabetes Obes Metab，2005，7(6)：692-698.
[7]Utzschneider KM，Tong J，Montgomery B，et al. The dipeptidyl peptidase-4 inhibitor vildagliptin inproves beta-cell function and insulin sensitivity in sujects with impaired fasting glucose [J]. Diabetes Care，2008，31(1)：108-113.
, 百拇医药
[8]Scherbaum A，SchweizerA，Mari P，et al. Efficacy and tolerability of vildagliptin in drug-na1ve patients with type 2 diabetes and mild hyperglycaemia [J]. Diabetes Obes Metab，2008，10(8)：675-682.
[9]Foley JE，Bunck MC，Mller-Goede DL，et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia：a randomised controlled trial [J]. Diabetologia，2011，54(8)：1985-1991.
, http://www.100md.com
[10]Ahren B，Foley JE，Ferrannini E，et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy [J]. Diabetes Care，2010，33(4)：730-732.
[11]Ahren B，Pacini G，Foley J，et al. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase Ⅳ inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year [J]. Diabetes Care，2005，28(8)：1936-1940.
, http://www.100md.com
[12]Serra D，He YL，Bullock J，et al. Evaluation of pharmacokinetic and pharmcodynamic interaction between the dipeptidyl peptidase Ⅳ inhibitor Vildagliptin，Glyburide and Pioglitazone in patients with type 2 diabetes [J]. Int J Clin Pharmacol Ther，2008，46(7)：349-364.
[13]Jeon HJ. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients [J]. Diabetes Metab J，2011，35(5)：529-535.
[14]Matthews DR，Dejager S，Aren B，et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride，with no weight gain：results from a 2-year study [J]. Diabetes Obes Metab，2010，12(9)：780-789.
, 百拇医药
[15]Banerji MA，Purkayastha D，Francis BH，et al. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment：a retrospective analysis of the GALIANT study [J]. Diabetes Res Clin Pract，2010，90(2)：182-190.
[16]Ahren B，Gomis R，Standl E，et al. Twelve-and 52-weeks efficacy of the dipeptidyl peptidase IV inhibitorLAF237 in metformin-treated patients with type 2 diabetes [J]. Diabetes Care，2004，27(12)：2874-2880. [17]Barilla D，He YL，Balez S，et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide [M]. Orlando，FL：64th Scientific Session of the American Diabetes Association，2004：981-985.
(收稿日期：2011-12-13本文编辑：张瑜杰), http://www.100md.com(樊建领 焦伟杰)
[参考文献]
[1]Mclntosh CH，Demuth HU，Kim SJ，et al. Applications of dipeptidyl peptidase Ⅳ inhibitors in diabetes mellitus [J]. Int J Biochem Cell Biol，2006，38(5-6)：860-872.
[2]Kiffer TJ，McIntosh CH，Pederson TA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl Peptidase Ⅳ[J]. Endocrin，1995，136(8)：3585-3596.
, http://www.100md.com
[3]Tran P，Yin H，Smith T，et al. Disposition of LAF237 in rats and humans [J]. Drug Metab Rev，2002，34(Suppl)：147.
[4]Villhanuer EB，Brinkman JA，Naderi GB，et al. I-[[(3-hydroxy-l-adamantyI)amino] acetyI]-2-cyano-(S)-pyrrolidine；a potent，selective，and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyper glycemic properties [J]. J Med Chem，2003，46(13)：2774-2789.
[5]He YL，Sabo R，Wang G，et al. The hepatic impairment on the pharmacokinetics of vildagliptin [M]. Washington，DC：66th Scientific Session of the American Diabetes Association，2006：1176-1179.
, 百拇医药
[6]Ristic S，Byiers S，Foley J，et al. Improved glycemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes：vildagliptin(LAF237)dose response [J]. Diabetes Obes Metab，2005，7(6)：692-698.
[7]Utzschneider KM，Tong J，Montgomery B，et al. The dipeptidyl peptidase-4 inhibitor vildagliptin inproves beta-cell function and insulin sensitivity in sujects with impaired fasting glucose [J]. Diabetes Care，2008，31(1)：108-113.
, 百拇医药
[8]Scherbaum A，SchweizerA，Mari P，et al. Efficacy and tolerability of vildagliptin in drug-na1ve patients with type 2 diabetes and mild hyperglycaemia [J]. Diabetes Obes Metab，2008，10(8)：675-682.
[9]Foley JE，Bunck MC，Mller-Goede DL，et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia：a randomised controlled trial [J]. Diabetologia，2011，54(8)：1985-1991.
, http://www.100md.com
[10]Ahren B，Foley JE，Ferrannini E，et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy [J]. Diabetes Care，2010，33(4)：730-732.
[11]Ahren B，Pacini G，Foley J，et al. Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase Ⅳ inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year [J]. Diabetes Care，2005，28(8)：1936-1940.
, http://www.100md.com
[12]Serra D，He YL，Bullock J，et al. Evaluation of pharmacokinetic and pharmcodynamic interaction between the dipeptidyl peptidase Ⅳ inhibitor Vildagliptin，Glyburide and Pioglitazone in patients with type 2 diabetes [J]. Int J Clin Pharmacol Ther，2008，46(7)：349-364.
[13]Jeon HJ. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients [J]. Diabetes Metab J，2011，35(5)：529-535.
[14]Matthews DR，Dejager S，Aren B，et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride，with no weight gain：results from a 2-year study [J]. Diabetes Obes Metab，2010，12(9)：780-789.
, 百拇医药
[15]Banerji MA，Purkayastha D，Francis BH，et al. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment：a retrospective analysis of the GALIANT study [J]. Diabetes Res Clin Pract，2010，90(2)：182-190.
[16]Ahren B，Gomis R，Standl E，et al. Twelve-and 52-weeks efficacy of the dipeptidyl peptidase IV inhibitorLAF237 in metformin-treated patients with type 2 diabetes [J]. Diabetes Care，2004，27(12)：2874-2880. [17]Barilla D，He YL，Balez S，et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide [M]. Orlando，FL：64th Scientific Session of the American Diabetes Association，2004：981-985.
(收稿日期：2011-12-13本文编辑：张瑜杰), http://www.100md.com(樊建领 焦伟杰)